CD274 and small cell lung carcinoma: Given the prospect of PD-L1 evaluation to impact clinical outcomes of SCLC patients treated with ICIs, there is a need for large, longitudinal, multicentre studies with well-defined protocols and endpoints to advance the clinical value of PD-L1 expression.